Supplemental material
Expert Opinion on Drug Safety
Volume 21, 2022 - Issue 10
Open access
2,164
Views
0
CrossRef citations to date
0
Altmetric
Original Research
Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study
Daisuke Yabea Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan;b Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan;c Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Kobe, Japan;d Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japanhttps://orcid.org/0000-0002-5334-7687View further author information
, Fumiko Yamamotoe Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanCorrespondence[email protected]
View further author information
, View further author information
Søren S. Lundf Boehringer Ingelheim International GmbH, Ingelheim, GermanyView further author information
, Tomoo Okamurae Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanView further author information
& Takashi Kadowakig President, Toranomon Hospital, Tokyo, JapanCorrespondence[email protected]
View further author information
View further author information
Pages 1303-1313
|
Received 01 Dec 2021, Accepted 22 Mar 2022, Published online: 03 May 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.